Q1 2025 Compugen Ltd Earnings Call Transcript
Key Points
- Compugen Ltd (CGEN) has initiated a sub-trial for their anti-PVRIG antibody COM701 in ovarian cancer, targeting an unmet medical need.
- The company has a strong cash position with a runway extending into 2027, supporting their clinical and research activities.
- Compugen Ltd (CGEN) is advancing its early-stage and clinical immuno-oncology pipeline, focusing on innovative therapies.
- Partnership with AstraZeneca is progressing, with multiple Phase 3 trials initiated, potentially leading to significant revenue opportunities.
- The company is exploring novel mechanisms of action in their early-stage pipeline, aiming to enhance anticancer immunity.
- Revenues for the first quarter of 2025 decreased compared to the same period in 2024.
- The company reported a net loss of approximately $7.2 million for the first quarter of 2025.
- There is uncertainty in the TIGIT landscape, with previous Phase 3 failures impacting market sentiment.
- The success of Compugen Ltd (CGEN)'s TIGIT program is contingent on positive outcomes from upcoming Phase 3 trials.
- The competitive landscape in ovarian cancer is evolving, with new therapies potentially impacting Compugen Ltd (CGEN)'s strategy.
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's first quarter 2025 results conference call. (Operator Instructions) An audio webcast of this call is available in the Investors section of Compugen's website, www.cgen.com. As a reminder, today's call is being recorded.
I would now like to introduce Yvonne Naughton, Vice President, Head of Investor Relations and Corporate Communications. Yvonne, please go ahead.
Thank you, operator, and thank you all for joining us on the call today. Joining me from Compugen for the prepared remarks are Dr. Anat Cohen-Dayag, President and Chief Executive Officer; and David Silberman, Chief Financial Officer. Dr. Michelle Mahler, Chief Medical Officer; and Dr. Eran Ophir, Chief Scientific Officer, will join us for the Q&A.
Before we begin, we would like to remind you that during this call, the company may make projections of forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
